Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Novelix Pharma.
Quarter-by-quarter operating performance
| Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 0.43 | 0.87 | 1.95 | 0.93 | 0.50 | 0.84 | 0.60 | 3.96 | 5.30 | 20.86 | 22.35 | 36.36 | 48.40 |
| Expenses + | 0.52 | 1.07 | 2.14 | 1.04 | 0.61 | 0.69 | 1.04 | 3.74 | 5.17 | 20.63 | 22.17 | 35.66 | 47.09 |
| Operating Profit | -0.09 | -0.20 | -0.19 | -0.11 | -0.11 | 0.15 | -0.44 | 0.22 | 0.13 | 0.23 | 0.18 | 0.70 | 1.31 |
| OPM % | -20.93% | -22.99% | -9.74% | -11.83% | -22.00% | 17.86% | -73.33% | 5.56% | 2.45% | 1.10% | 0.81% | 1.93% | 2.71% |
| Other Income + | 0.18 | 0.23 | 0.05 | 0.05 | 0.09 | 0.13 | 0.10 | -0.08 | 0.00 | 0.00 | 0.00 | 0.03 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 | 0.01 | 0.03 |
| Profit before tax | 0.07 | 0.02 | -0.15 | -0.07 | -0.03 | 0.27 | -0.34 | 0.14 | 0.13 | 0.21 | 0.17 | 0.72 | 1.28 |
| Tax % | 0.00% | 0.00% | 6.67% | 0.00% | 0.00% | 0.00% | 2.94% | 0.00% | -15.38% | 14.29% | 41.18% | 26.39% | 21.88% |
| Net Profit + | 0.07 | 0.01 | -0.17 | -0.07 | -0.03 | 0.28 | -0.35 | 0.13 | 0.15 | 0.18 | 0.11 | 0.53 | 1.00 |
| EPS in Rs | 0.09 | 0.01 | -0.21 | -0.09 | -0.04 | 0.35 | -0.35 | 0.13 | 0.15 | 0.18 | 0.09 | 0.37 | 0.58 |
Financials of Novelix Pharma.
Annual income statement trend
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 6 | 1 | 1 | 4 | 3 | 4 | 2 | 1 | 1 | 2 | 4 | 31 | 128 |
| Expenses + | 5 | 1 | 1 | 3 | 3 | 3 | 1 | 4 | 3 | 2 | 4 | 31 | 126 |
| Operating Profit | 1 | 0 | 0 | 0 | 0 | 0 | 0 | -3 | -2 | 0 | -0 | 0 | 2 |
| OPM % | 16% | 33% | 43% | 5% | 15% | 6% | 12% | -244% | -151% | 0% | -6% | 0% | 2% |
| Other Income + | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 1 | 0 | 0 | 0 | 0 | 0 | 0 | -3 | -2 | -0 | 0 | 0 | 2 |
| Tax % | 32% | 88% | 31% | 24% | 34% | -32% | 20% | 0% | -1% | 0% | 50% | 33% | |
| Net Profit + | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -3 | -2 | -0 | 0 | 0 | 2 |
| EPS in Rs | 0.52 | 0.02 | 0.12 | 0.19 | 0.22 | 0.31 | 0.11 | -4.04 | -1.93 | -0.07 | 0.01 | 0.08 | 1.22 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Financials of Novelix Pharma.
Capital structure and asset base
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 10 | 14 |
| Reserves | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 1 | -1 | -1 | -1 | 8 | 11 |
| Borrowings + | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities + | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 46 |
| Total Liabilities | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 9 | 7 | 7 | 7 | 27 | 72 |
| Fixed Assets + | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 1 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 1 | 3 | 2 | 3 | 3 | 4 | 4 | 1 | 3 | 3 | 0 | 0 |
| Other Assets + | 10 | 9 | 8 | 9 | 9 | 9 | 8 | 5 | 5 | 4 | 4 | 27 | 71 |
| Total Assets | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 9 | 7 | 7 | 7 | 27 | 72 |
Financials of Novelix Pharma.
Operating, investing and financing cash movement
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 0 | -0 | 2 | -1 | 1 | -0 | 1 | 1 | 1 | -2 | -0 | -14 |
| Cash from Investing Activity + | 0 | -0 | -2 | 1 | -1 | 0 | -0 | 0 | 0 | 0 | 0 | 3 |
| Cash from Financing Activity + | -0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11 |
| Net Cash Flow | 0 | -1 | 0 | -0 | -0 | 0 | 1 | 1 | 1 | -2 | -0 | 1 |
| Free Cash Flow | -0 | -1 | 2 | -1 | 1 | -0 | 1 | 0 | -1 | -2 | -0 | -14 |
| CFO/OP | 3% | -90% | 472% | -535% | 225% | -220% | 672% | -18% | -34% | 136% | -9,771% |
Financials of Novelix Pharma.
Working capital efficiency and return ratios
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 54 | 30 | 4 | 40 | 130 | 216 | 19 | 25 | 32 | 36 | 1 | 216 |
| Inventory Days | 28 | 0 | 28 | 19 | 13 | 39 | 89 | 239 | 222 | 113 | 10 | |
| Days Payable | 4 | 0 | 54 | 13 | 5 | 4 | 0 | 14 | 0 | 115 | ||
| Cash Conversion Cycle | 77 | 30 | 4 | 68 | 95 | 216 | 54 | 111 | 271 | 244 | 114 | 111 |
| Working Capital Days | 571 | 2,225 | 2,584 | 863 | 932 | 858 | 1,711 | 819 | 647 | 743 | 346 | 197 |
| ROCE % | 5% | 1% | 1% | 1% | 3% | 1% | 1% | -31% | -19% | -1% | 0% | 1% |
Volume-led growth with inpatient (IP) volumes up 39% and outpatient (OP) volumes up 26% year-on-year. Key concall takeaways from Manipal Health Enterprises…
IHH plans to increase its stake in Fortis to over 50% within 3-5 years, supporting long-term strategic growth. Key concall takeaways from Fortis Healthcare…
East India currently 6%, with limited investment so far; future investments may increase contribution. Key concall takeaways from Metropolis Healthcare Ltd's…
IP volume growth for established units guided at roughly 7% to 8%. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q1 FY27 earnings call — and how…